Top Qs
Timeline
Chat
Perspective
Cosibelimab
Medication From Wikipedia, the free encyclopedia
Remove ads
Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma.[1] It is a human immunoglobulin G1 (IgG1) programmed death ligand-1 (PD-L1) blocking antibody.[1]
The most common adverse reactions include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritis, edema, localized infection, and urinary tract infection.[2]
Cosibelimab was approved for medical use in the United States in December 2024.[1][2][3][4]
Remove ads
Medical uses
Cosibelimab is indicated for the treatment of adults with metastatic cutaneous squamous-cell carcinoma or locally advanced cutaneous squamous-cell carcinoma who are not candidates for curative surgery or curative radiation.[1][2]
History
Efficacy was evaluated in study CK-301-101 (NCT03212404), a multicenter, multicohort, open-label trial in 109 participants with metastatic cutaneous squamous-cell carcinoma or locally advanced cutaneous squamous-cell carcinoma who were not candidates for curative surgery or curative radiation.[2] Participants were excluded if they had any of the following: active or suspected autoimmune disease, allogeneic transplant within six months prior to treatment, prior treatment with anti-PD-1/PD-L1 blocking antibodies or other immune checkpoint inhibitor therapy, uncontrolled or significant cardiovascular disease, ECOG PS • 2, or infection with HIV, hepatitis B, or hepatitis C.[2]
Remove ads
Society and culture
Legal status
Cosibelimab was approved for medical use in the United States in December 2024.[2][5]
Names
Cosibelimab is the international nonproprietary name.[6]
Cosibelimab is sold under the brand name Unloxcyt.[1]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads